PRICENTRIC BRIEF:
- The Global Antibiotic Research and Development Partnership (GARDP) has teamed up with the Clinton Health Access Initiative (CHAI) and Shionogi to bolster access to antibiotic Fetcroja (cefiderocol) for Gram-negative bacterial infections in low- and middle-income countries
- The tripartite collaboration seeks to assist governments and partners in introducing Fetcroja into health systems, providing clinical guidance, training, and other details to ensure appropriate use of the antibiotic
- Dr. Subasree Srinivasan, Medical Director, GARDP, said, “This collaboration with CHAI and Shionogi aims to improve our ability to reach vulnerable people, including in low- and middle-income countries, with an antibiotic for serious infections with limited treatment options, and to ensure its use is governed by principles of appropriate and sustainable access”
THE DETAILS
GENEVA, Switzerland – The Global Antibiotic Research and Development Partnership (GARDP) has teamed up with the Clinton Health Access Initiative (CHAI) and Shionogi to bolster access to antibiotic Fetcroja (cefiderocol) for Gram-negative bacterial infections in low- and middle-income countries.
The tripartite collaboration seeks to assist governments and partners in introducing Fetcroja into health systems, providing clinical guidance, training, and other details to ensure appropriate use of the antibiotic.
A siderophore cephalosporin, Fetcroja has been approved for use in the United States and European Union against multi-drug resistant Gram-negative bacterial infections. GARDP called it a potentially “valuable took to treat…resistant infections,” especially considering the growing threat of antimicrobial resistance (AMR), which leads to more than 700,000 deaths each year.
Dr. Subasree Srinivasan, Medical Director, GARDP, said, “This collaboration with CHAI and Shionogi aims to improve our ability to reach vulnerable people, including in low- and middle-income countries, with an antibiotic for serious infections with limited treatment options, and to ensure its use is governed by principles of appropriate and sustainable access.”
Takuko Sawada, Director of the Board, Executive Vice President, Shionogi & Co., Ltd, commented, “In addition to improving access, it is important to address environment health challenges, improve diagnosis and secure appropriate use. GARDP and CHAI have tremendous local knowledge and infrastructure which will be critical to help address AMR on a global basis.”
Dr. David Ripin, Chief Science Officer and Executive Vice President Infectious Diseases, Clinton Health Access Initiative, added, “Through this initiative we have the chance to combat the silent pandemic of antimicrobial resistance and ensure access to the newest treatments for patients regardless of where they live.”
了解更多 Pricentric ONE 和我们的 全球定价解决方案!
联系我们 提出您的问题和全球定价需求，我们的专家将尽快跟进。